GRAIL at Morgan Stanley conference: FDA, coverage seen as key

On Monday, 14 September 2026, at the Morgan Stanley 24th Annual Global Healthcare Conference, Belite Bio unveiled its hopes for tinlarebant, a potential treatment for Stargardt disease. The company presented strong Phase III data and a near-term U.S. decision date, while also noting that regulatory approval is still pending. Tinlarebant is currently under FDA review for Stargardt disease, with a Priority Review designation and a February 12 PDUFA date.

Belite Bio highlighted the DRAGON Phase III study, which demonstrated a 36% reduction in lesion progression over two years compared to placebo, with a favorable safety profile. The mechanism of action involves targeting the RBP receptor, unique to the eye and crucial for controlling vitamin A access. By lowering retinol bound to retinol-binding protein 4, tinlarebant aims to reduce toxic A2E buildup and other damaging bisretinoids in Stargardt disease.

The FDA has accepted decreased autofluorescence (DDAF) as an approvable endpoint, and Belite Bio submitted a confirmatory evidence package, including natural history data from ProgStar, fellow-eye data, and other supporting material. The company expects the FDA to be familiar with Stargardt disease and DDAF as an endpoint, having previously approved another drug based on this type of measure.

Belite Bio emphasized the drug's safety, noting that side effects are expected and manageable with counseling. Approximately one-third of patients experienced delayed dark adaptation and dyschromatopsia, which were described as reversible if therapy is discontinued. The company is preparing for a potential commercial launch, focusing on specialist education, disease awareness, and payer engagement.